Katzenell Dimant /

KD represents SteadyMed in $32 Million Private Placement



Our client SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, announced that it has entered into definitive agreements to sell shares of its common stock and warrants to purchase shares of its common stock for aggregate gross proceeds of up to approximately $32 million in a two-tranche private placement.

The financing was led by new investor OrbiMed with participation from existing investors including, Federated Investors, Inc. and Deerfield Management.

Read the press on Globes [English].


read more in: